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Background: Bifurcationstenting is technically challengingandside
branch compromise is a major determinant of lower procedural
success rates and adverse outcomes. We sought to compare the
incidenceof sidebranchcompromiseusingopencell designstentvs
closed cell design in patients undergoing PCI major bifurcation le-
sions using the provisional stenting approach (single stent strategy)
approach, and also the outcome of the significant side branch oc-
clusion in terms of periprocedural MI, new onset RWMA.
Methods: This is a retrospective observational study of consecu-
tive patients conducted MCH Trivandrum from Oct 2013 to April
2014. All patients who underwent coronary angiogram (CAG)& PCI
during the study period was screened, among them those planned
for bifurcation PCI with single stent strategy was included in the
study. Detailed history, physical, electrocardiographic, echocar-
diographic examination and laboratory examination results were
included. Then study population were divided into two group
based on whether they received closed or open cell design stent.
The incidence of significant side branch compromise was evalu-
ated in the each group. Post-procedural serial ECGs, cardiac en-
zymes and echocardiography were done in all patients.
Results: The mean age of study population was 56± 9years, also
mean age of the both sub group was 56± years. Males were pre-
dominant, accounting 79% of entire study population. Diabetes
mellituswaspresent in52% inopencell designand50% inclosedcell
design group. Most common indication for PCI was STEMI (44%),
followed by NSTEMI, Unstable angina (33% each). Majority had
Single vessel disease (59%), 34%had two vessel disease, three vessel
diseasewas present only in 7% of patient. Themost common site of
the bifurcation lesion is LAD ediagonal, followed by LCX-OM. Most
common type of bifurcation classification is 1.1.0(59%), followed by
1.1.1(32%). Mean size of the side branch in open cell design group
was 2.33 mm, and 2.29 in closed cell design group. There was no
significantdifference inbaseline characteristicbetween twogroups.
Out of total 118 bifurcation PCI, 9 patient had side branch
compromise ,out of which 5(55%) had periprocedural MI. Out of 9
nine branch compromise occurred, 3 had occurred in open cell
design stent group and 6 occurred in closed cell design stent
group, there is no significant difference between the groups-
probably due to small numbers.
Conclusion: Our study did not show any difference in the rate of
side branch compromise between the study groups. In accordance
withmost of the trials, our study showed side branch compromise
was commonwhen side branch size less than 2.5mm. Only 50% of
patient who had side branch compromise had periprocedural MI.
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Background: Plaque rupture is mediated by effector CD4 T(Tcon)
cells which are normally inhibited by regulatory T cells (Treg).
Studies on Treg cell count in ST elevation myocardial infarction
(STEMI) have reported conflicting results.
Aim: To assess Treg/Tcon cell balance in STEMI patients along
with pro-inflammatory (IL 6 and TNF alpha) and anti-inflamma-
tory cytokine (IL 10).
Methods: 15 patients of STEMI along with 15 controls have been
studied till date (study is ongoing and aim is to enroll 30 patients).
Apart from peripheral blood (PB), Treg and Tcon cells were also
assessed from infarct related artery (IRA) by flowcytometry as no
study till date has assessed these cells in IRA.
Results: Mean age of patients was 47.46 ± 9.8 yrs. Mean duration
from symptom onset to sample collection was 7.5±2.2 hrs. In
cases, there was significant increase in both Treg and Tcon cells
but balance of Treg/Tcon was favourable (0.77±1.23 versus
0.22±0.19 in control (p¼ 0.50). Treg cell was significantly higher in
both PB (4.17±2.46 %,p<0.001) and IRA (4.69±4.72 %,P<0.001) versus
control (1.17±1.1 %), along with Tcon (14.40±10.29 % in
PB,16.23±9.86 % in IRA,P¼0.03) versus control (5.26±2.63 %) with
no significant difference between PB and IRA.There was also sig-
nificant increase of both anti-inflammatory cytokine in cases(IL
1030.78±50.54 pg/ml,versus 0.89±0.37 pg/ml p<0.001) along with
pro-inflammatory cytokine (IL 632.78±33.82pg/ml versus
3.05±2.59pg/ml p<0.001 and TNF alpha 39.05±57.91 pg/ml,versus
7.54±5.41 pg/ml p¼0.017) but ratio of anti-inflammatory (IL 10) to
pro-inflammatory cytokines (IL 6) increased from 0.493±0.489 in
control to 0.872±1.167 in patients (P¼NS).
Conclusion: Ratio of Treg/Tcon cell along with anti/pro-inflam-
matory cytokines increases in attempt to decrease the inflam-
matory damage in the initial stages of STEMI. So strategies to
augment Treg cell number or function may attenuate myocardial
damage till definite reperfusion therapy can be initiated.
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Background: Till recently clopidogrel has been the only available
antiplatelet drug used along with aspirin in patients of ACS. Now
two more antiplatelet drugs have become available in the form of
prasugrel (thienopyridine) and Ticagrelor (Non thienopyridine).
Prasugrel in the dose of 10 mg OD has been found to be more effi-
cacious but with increased risk of bleeding. So far the drug has not
gained widespread usage in ACS patients undergoing PCI. There
areno systematic data on theuseof Prasugrel in Indianpopulation.
Methods: This is a prospective, multicentric, hospital registry. A
minimum of 1000 patientswith ACS undergoing PCI whowould be
taking Prasugrel will be included in the study. The primary safety
endpoint of this study is major and minor bleeding while the ef-
ficacy endpoint is the composite of CV death, nonfatal MI,
nonfatal stroke up to 30 days after PCI.
Results: The requisite enrolment has been completed. Out of
which primary outcome is available for 864 patients. The average
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